Thursday, January 05, 2017 9:14:35 AM
They have opioids in the UK. The ActiPatch doesn't cure opioid addiction. The ActiPatch is a low-powered PEMF device that provides some benefit to some people -- not enough benefit to make it a retail success as proven in the UK.
Unless BIEL can lower their price to, say, $15. If a company could lower its price to $15 they might hit the sweet spot in the Demand Curve and turn a profit selling the ActiPatch OTC. Possibly. A meager profit, but a profit nonetheless.
It won't be BIEL though, IMO. BIEL is toast.
I see nothing here to LOL about.
FEATURED Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM
Fifty 1 Labs, Inc. Launches Dedicated Website for Shareholders and Investors, Company now current with OTC Markets • CAFI • Jan 7, 2025 9:00 AM
EzFill Holdings, Inc. Successfully Closes Acquisition of Shell Fleet, Accelerating Nationwide Mobile Fueling Expansion • EZFL • Jan 7, 2025 8:35 AM
CGRA Signs Binding Term Sheet to Merge With American Infrastructure Corporation, a Subsidiary of Nasdaq-listed American Resources Corporation (Nasdaq: AREC) • CGRA • Jan 6, 2025 10:31 AM
UAV Corp (UMAV) Working on Securing $1.5 Billion in Contracts and Announces Groundbreaking Partnership with Atlantic Industrial Group • UMAV • Jan 6, 2025 9:26 AM